194 related articles for article (PubMed ID: 12207609)
1. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Lee MW; Seo CW; Kim SW; Yang HJ; Lee HW; Choi JH; Moon KC; Koh JK
Acta Derm Venereol; 2004; 84(1):23-6. PubMed ID: 15040473
[TBL] [Abstract][Full Text] [Related]
3. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Fernandez-Galar M; España A; López-Picazo JM
Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
[TBL] [Abstract][Full Text] [Related]
4. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
Gencoglan G; Ceylan C
Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
[TBL] [Abstract][Full Text] [Related]
5. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Treudler R; Zouboulis CC
Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
[No Abstract] [Full Text] [Related]
6. [Acneiform eruption from epidermal growth factor receptor inhibitors].
Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
[TBL] [Abstract][Full Text] [Related]
7. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
8. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
9. [Skin signs associated with epidermal growth factor inhibitors].
Hannoud S; Rixe O; Bloch J; Le Pelletier F; Lebrun-Vignes B; Doarika A; Khayat D; Chosidow O
Ann Dermatol Venereol; 2006 Mar; 133(3):239-42. PubMed ID: 16800173
[TBL] [Abstract][Full Text] [Related]
10. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
11. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
Warthan MM; Jumper CA; Smith JL
J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
[TBL] [Abstract][Full Text] [Related]
12. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
13. [Gefitinib-induced perforating dermatosis].
Fernández-Guarino M; Aldanondo I; González-García C; Garrido P; Marquet A; Pérez-García B; Jaén P
Actas Dermosifiliogr; 2006 Apr; 97(3):208-11. PubMed ID: 16796971
[TBL] [Abstract][Full Text] [Related]
14. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
15. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
16. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Zhao Q; Wang YN; Wang B
Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
[TBL] [Abstract][Full Text] [Related]
17. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
18. Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
Miyawaki S; Tohyama M; Irifune K; Ito R; Sayama K
Int Wound J; 2014 Oct; 11(5):569-70. PubMed ID: 23517492
[No Abstract] [Full Text] [Related]
19. [Epidermal growth factor receptor inhibitors side effects].
Guhl G; González-de Arriba A; Daudén E
Actas Dermosifiliogr; 2006 Jun; 97(5):296-310. PubMed ID: 16956561
[TBL] [Abstract][Full Text] [Related]
20. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
